Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA clears Trodelvy as a first-line treatment for triple-negative breast cancer

FDA clears Trodelvy as a first-line treatment for triple-negative breast cancer

New Capabilities

A drug once reserved for late-stage patients moves to the front of the treatment line, alone or paired with Keytruda

June 24th, 2026: FDA approves Trodelvy as first-line treatment

Overview

Updated Jun 25

Triple-negative breast cancer is aggressive and short on options. On June 24, 2026, the U.S. Food and Drug Administration cleared Gilead Sciences' Trodelvy as a first-line treatment, moving a drug once used only after other therapies failed to the front of the line. Six days earlier, the European Commission had done the same for patients in the EU who are ineligible for immunotherapy.

Triple-negative tumors lack the three receptors that most breast-cancer drugs target, so hormone therapies and HER2 drugs don't work. The FDA cleared Trodelvy alone for patients who can't take immunotherapy, and alongside Merck's Keytruda for PD-L1-positive tumors. The National Comprehensive Cancer Network had already added both regimens as preferred first-line options in early 2026, before the FDA formally acted.

Why it matters

Patients with the hardest-to-treat breast cancer now have a targeted drug as their first option, not their last.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

38%
Lower risk of progression (alone)
ASCENT-03 cut the risk of cancer worsening or death by 38% versus chemotherapy.
35%
Lower risk of progression (with Keytruda)
ASCENT-04 cut that risk by 35% versus Keytruda plus chemotherapy.
16.5 mo
Median response duration (combo)
Trodelvy plus Keytruda held responses for 16.5 months versus 9.2 for the older regimen.
~15%
Share of breast cancers
Triple-negative disease is about one in seven breast cancers and skews younger.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Sara Tolaney
Sara Tolaney
Lead investigator, ASCENT breast cancer trials
Chief of breast oncology, Dana-Farber Cancer Institute

Organizations Involved

Gilead Sciences
Gilead Sciences
Biopharmaceutical company
Maker of Trodelvy; holds the new first-line approval

A California drugmaker that gained Trodelvy through its 2020 purchase of Immunomedics.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Granted both first-line approvals

The U.S. agency that decides which drugs can be sold and for which patients.

Timeline

April 2020 June 2026

6 events Latest: June 24th, 2026 · 3 months ago
Tap a bar to jump to that date

  1. FDA approves Trodelvy as first-line treatment

    Latest Regulatory

    The agency cleared Trodelvy alone for immunotherapy-ineligible patients and with Keytruda for PD-L1-positive tumors.

  2. European Commission approves Trodelvy for first-line TNBC

    Regulatory

    The EC granted marketing authorization for Trodelvy as monotherapy for patients with unresectable or metastatic TNBC not eligible for PD-(L)1 inhibitor therapy. It is the first antibody-drug conjugate cleared for first-line TNBC across the EU's 27 member states, plus Norway, Iceland, and Liechtenstein.

  3. NCCN adds Trodelvy to preferred first-line options

    Clinical Guideline

    The National Comprehensive Cancer Network updated its breast cancer guidelines (Version 1.2026) to list Trodelvy as a Category 1 preferred option for PD-L1-negative first-line metastatic TNBC. The Trodelvy-plus-Keytruda combination was added as Category 2A preferred for PD-L1-positive disease.

  4. First-line trial data reported

    Clinical Data

    ASCENT-03 and ASCENT-04 results showed the drug slowed cancer better than chemotherapy as an opening treatment.

  5. Full approval after ASCENT trial

    Regulatory

    The Phase 3 ASCENT trial showed longer survival, and the FDA converted the drug to regular approval for later-line use.

  6. Trodelvy wins accelerated approval

    Regulatory

    The FDA cleared Trodelvy for triple-negative patients who had already tried at least two prior therapies.

Scenarios

1

Trodelvy first-line shows a clear overall survival benefit

Possible Resolves by Q2 2027

Discussed by: Gilead, ASCO Post, oncology trial reports

The ASCENT-03 and ASCENT-04 trials measured how long patients lived, not just how long their cancer stayed in check. If the mature survival data show patients on Trodelvy living meaningfully longer than those on chemotherapy, the drug's case as a default first treatment hardens and guidelines follow quickly.

2

NCCN names Trodelvy a preferred first-line option

Likely Resolves by End of 2026

Discussed by: Oncology practice analysts, NCCN guideline watchers

U.S. cancer centers follow National Comprehensive Cancer Network (NCCN) guidelines closely. An approval alone does not change daily practice; a guideline listing does. If NCCN updates its breast cancer guidance to name Trodelvy a preferred first-line choice for metastatic triple-negative disease, uptake spreads fast across clinics.

3

A rival Trop-2 drug wins first-line approval

Uncertain Resolves by End of 2027

Discussed by: Precision Medicine Online, oncology market analysts

Trodelvy targets a tumor protein called Trop-2. AstraZeneca and Daiichi Sankyo are developing datopotamab deruxtecan (Datroway), a competing Trop-2 antibody-drug conjugate also studied in breast cancer. If the FDA clears that rival for first-line metastatic triple-negative disease, Trodelvy loses its solo standing and the two enter direct competition.

4

EU clears Trodelvy plus Keytruda for PD-L1-positive TNBC

Likely Resolves by Q2 2027

Discussed by: Gilead Sciences investor filings, European Medicines Agency submission tracker

Gilead has submitted a supplemental application to the European Medicines Agency for Trodelvy in combination with Keytruda for first-line PD-L1-positive metastatic TNBC, based on ASCENT-04 data. If the EMA recommends approval and the EC grants marketing authorization, European patients with PD-L1-positive tumors gain the same combination option now available in the U.S.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 1998

Herceptin approval (1998)

The FDA approved trastuzumab, sold as Herceptin, for breast tumors that overexpress the HER2 protein. It was the first drug to attack a specific molecular target in breast cancer rather than poison dividing cells broadly. A once grim subtype became one of the more treatable ones.

Then

Patients with HER2-positive cancer gained a targeted option that worked where chemotherapy alone often failed.

Now

Herceptin proved that matching a drug to a tumor's biology could reset survival odds, opening the targeted-therapy era in cancer.

Why this matters now

Trodelvy follows the same logic for triple-negative disease: a drug aimed at a tumor protein, moved early to change the default treatment.

November 2020

Keytruda first-line TNBC approval (2020)

The FDA cleared Merck's Keytruda with chemotherapy as a first treatment for metastatic triple-negative breast cancer in tumors carrying the PD-L1 marker. It was the first immunotherapy approved for first-line use in this disease, based on the KEYNOTE-355 trial.

Then

PD-L1-positive patients gained an immune-based option at the start of treatment.

Now

It split triple-negative care by biomarker and set the stage for combination regimens like the new Trodelvy-plus-Keytruda pairing.

Why this matters now

The 2026 approval builds directly on this, adding Trodelvy to Keytruda for the same PD-L1-positive group.

August 2022

Enhertu HER2-low approval (2022)

The FDA approved trastuzumab deruxtecan, sold as Enhertu, for breast cancers with low HER2 levels once thought untreatable by HER2 drugs. The antibody-drug conjugate carried a chemotherapy payload straight to tumor cells. The DESTINY-Breast04 trial showed a survival gain.

Then

A large group of patients previously labeled HER2-negative gained access to a targeted drug.

Now

It cemented antibody-drug conjugates as a major breast cancer class and pushed makers to test them earlier.

Why this matters now

Trodelvy is the same kind of drug, an antibody-drug conjugate, and its first-line move reflects the wider shift toward using these earlier.

Sources

(10)
+4
U.S. Food and Drug Administration Gilead Sciences The ASCO Post CURE Business Wire OncLive U.S. Food and Drug Administration Gilead Sciences Gilead Sciences CURE Today